Group, PHOSP-COVID S C & Dark, P 2023, ' Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. ', EClinicalMedicine, vol. 57, no. 101896 . https://doi.org/10.1016/j.eclinm.2023.101896 McAuley, H J C, Evans, R A, Bolton, C E, Brightling, C E, Chalmers, J D, Docherty, A B, Elneima, O, Greenhaff, P L, Gupta, A, Harris, V C, Harrison, E M, Ho, L-P, Horsley, A, Houchen-Wolloff, L, Jolley, C J, Leavy, O C, Lone, N I, Man, W D-C, Marks, M, Parekh, D, Poinasamy, K, Quint, J K, Raman, B, Richardson, M, Saunders, R M, Sereno, M, Shikotra, A, Singapuri, A, Singh, S J, Steiner, M, Tan, A L, Wain, L V, Welch, C, Whitney, J, Witham, M D, Lord, J, Greening, N J, PHOSP-COVID Study Collaborative Group, Armour, C, Busby, J, Connolly, B, Drain, S, Grieve, D, Hart, N, Harvey, M, Heaney, L G, Hughes, J, Jones, M G, Magee, N, McArdle, A, McGarvey, L, Mills, C, Mitchell, J, Peto, T, Rowland, M, Sharma, M & Siddiqui, S 2023, ' Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study ', eClinicalMedicine, vol. 57, 101896 . https://doi.org/10.1016/j.eclinm.2023.101896
2022, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, pp. 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Liew, F, Talwar, S, Cross, A, Willett, B J, Scott, S, Logan, N, Siggins, M K, Swieboda, D, Sidhu, J K, Efstathiou, C, Moore, S C, Davis, C, Mohamed, N, Nunag, J, King, C, Thompson, A A R, Rowland-Jones, S L, Docherty, A B, Chalmers, J D, Ho, L-P, Horsley, A, Raman, B, Poinasamy, K, Marks, M, Kon, O M, Howard, L, Wootton, D G, Dunachie, S, Quint, J K, Evans, R A, Wain, L V, Fontanella, S, de Silva, T I, Ho, A, Harrison, E, Baillie, J K, Semple, M G, Brightling, C, Thwaites, R S, Turtle, L, Openshaw, P J M, ISARIC4C Investigators, Armour, C, Carson, G, Busby, J, Connolly, B, Cooper, J, Drain, S, Grieve, D, Hart, N, Harvey, M, Heaney, L G, Hughes, J, Jones, M G, Magee, N, McArdle, A, McGarvey, L, Mills, C, Mitchell, J, Peto, T, Powell, N, Rowland, M, Sharma, M & Siddiqui, S 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Horsley, A, Dark, P, Felton, T, et al, ISARIC4C Investigators & PHOSP-COVID Collaborative Group 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402
Zheng, B, Vivaldi, G, Daines, L, Leavy, O C, Richardson, M, Elneima, O, McAuley, H J C, Shikotra, A, Singapuri, A, Sereno, M, Saunders, R M, Harris, V C, Houchen-Wolloff, L, Greening, N J, Peffer, P E, Hurst, J R, Brown, J S, Shankar-Hari, M, Echevarria, C, De Soyza, A, Harrison, E M, Docherty, A B, Lone, N I, Quint, J K, Chalmers, J D, Ho, L-P, Horsley, A, Marks, M P, Poinasamy, K, Raman, B, Heaney, L G, Wain, L V, Evans, R A, Brightling, C E & Martineau, A R & Sheikh, A 2023, ' Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls ', The Lancet Regional Health-Europe, vol. 29, 100635 . https://doi.org/10.1016/j.lanepe.2023.100635 PHOSP-COVID Study Collaborative Group 2023, ' Determinants of recovery from post-COVID-19 dyspnoea : analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls ', The Lancet Regional Health-Europe . https://doi.org/10.1016/j.lanepe.2023.100635
Hynes, L, Murphy, A, Hart, N, Kirwan, C, Mulligan, S, Leathem, C, Maxwell, M, McQuillan, L, Carr, E, Walkin, S, McCarthy, C, Bradley, C, Byrne, M, Smith, S, Hughes, C, Corry, M, Kearney, P M, McCarthy, P, Cupples, M, Gillespie, P, Newell, J, Glynn, L, Alvarez-Iglesias, A & Sinnott, C 2022, ' The MultimorbiditY COllaborative Medication Review And DEcision Making (MyComrade) study: A protocol for a cross-border pilot cluster randomised controlled trial. ', Pilot and Feasibility Studies, vol. 8, 73 . https://doi.org/10.1186/s40814-022-01018-y